REFERENCES
1. Roep BO, Thomaidou S, van Tienhoven R, Zaldumbide A. Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?). Nat Rev Endocrinol. 2021;17:150-61.
2. Zhang J, Lin C, Jin S, et al. The pharmacology and therapeutic role of cannabidiol in diabetes. Exploration. 2023;3:20230047.
3. Mobasseri M, Shirmohammadi M, Amiri T, Vahed N, Hosseini Fard H, Ghojazadeh M. Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis. Health Promot Perspect. 2020;10:98-115.
4. Li Y, Sun F, Yue TT, et al. Revisiting the antigen-presenting function of β cells in T1D pathogenesis. Front Immunol. 2021;12:690783.
6. Primavera R, Kevadiya BD, Swaminathan G, et al. Emerging nano- and micro-technologies used in the treatment of type-1 diabetes. Nanomaterials. 2020;10:789.
7. Liu J, Zhou Y, Lyu Q, Yao X, Wang W. Targeted protein delivery based on stimuli-triggered nanomedicine. Exploration. 2024;4:20230025.
8. Lernmark A, Larsson HE. Immune therapy in type 1 diabetes mellitus. Nat Rev Endocrinol. 2013;9:92-103.
9. Goldman JD, Choi H. Teplizumab: the first treatment to delay the progression of type 1 diabetes. Clin Diabetes. 2023;41:474-6.
10. Veiseh O, Tang BC, Whitehead KA, Anderson DG, Langer R. Managing diabetes with nanomedicine: challenges and opportunities. Nat Rev Drug Discov. 2015;14:45-57.
11. Jing Z, Li Y, Ma Y, Zhang X, Liang X, Zhang X. Leverage biomaterials to modulate immunity for type 1 diabetes. Front Immunol. 2022;13:997287.
12. Feng C, Tan P, Nie G, Zhu M. Biomimetic and bioinspired nano-platforms for cancer vaccine development. Exploration. 2023;3:20210263.
13. Dai H, Fan Q, Wang C. Recent applications of immunomodulatory biomaterials for disease immunotherapy. Exploration. 2022;2:20210157.
14. Zhang K, Cheng K. Stem cell-derived exosome versus stem cell therapy. Nat Rev Bioeng. 2023;Online ahead of print.
15. Cheng K, Kalluri R. Guidelines for clinical translation and commercialization of extracellular vesicles and exosomes based therapeutics. Extracellular Vesicle. 2023;2:100029.
16. Li L, Wang F, Zhu D, Hu S, Cheng K, Li Z. Engineering exosomes and exosome-like nanovesicles for improving tissue targeting and retention. Fundamental Research. 2024;Online ahead of print.
17. Zhu D, Cheng K. Cardiac cell therapy for heart repair: should the cells be left out? Cells. 2021;10:641.
18. Ding Y, Wang Y, Hu Q. Recent advances in overcoming barriers to cell-based delivery systems for cancer immunotherapy. Exploration. 2022;2:20210106.
19. Soltani S, Mansouri K, Emami Aleagha MS, et al. Extracellular vesicle therapy for type 1 diabetes. Front Immunol. 2022;13:865782.
20. Sabry D, Marzouk S, Zakaria R, Ibrahim HA, Samir M. The effect of exosomes derived from mesenchymal stem cells in the treatment of induced type 1 diabetes mellitus in rats. Biotechnol Lett. 2020;42:1597-610.
21. Cantaluppi V, Biancone L, Figliolini F, et al. Microvesicles derived from endothelial progenitor cells enhance neoangiogenesis of human pancreatic islets. Cell Transplant. 2012;21:1305-20.
22. Liu M, Hu S, Yan N, Popowski KD, Cheng K. Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity. Nat Nanotechnol. 2024;19:565-75.
23. Liu H, Zhang X, Zhang M, et al. Mesenchymal stem cell derived exosomes repair uterine injury by targeting transforming growth factor-β signaling. ACS Nano. 2024;18:3509-19.
24. Popowski KD, López de Juan Abad B, George A, et al. Inhalable exosomes outperform liposomes as mRNA and protein drug carriers to the lung. Extracell Vesicle. 2022;1:100002.
25. Zhu D, Liu S, Huang K, et al. Intrapericardial exosome therapy dampens cardiac injury via activating Foxo3. Circ Res. 2022;131:e135-50.
26. Wang Z, Popowski KD, Zhu D, et al. Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine. Nat Biomed Eng. 2022;6:791-805.
27. Popowski KD, Dinh PC, George A, Lutz H, Cheng K. Exosome therapeutics for COVID-19 and respiratory viruses. View. 2021;2:20200186.
28. Fan M, Li H, Shen D, et al. Decoy exosomes offer protection against chemotherapy-induced toxicity. Adv Sci. 2022;9:e2203505.
29. Ding JT, Yang KP, Lin KL, Cao YK, Zou F. Mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetes. Front Endocrinol. 2022;13:1090842.
